{
    "organizations": [],
    "uuid": "51edf58e709dafece532f10f7588027521482436",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-enanta-pharmaceuticals-reports-q2/brief-enanta-pharmaceuticals-reports-q2-earnings-per-share-0-61-idUSASC0A0KK",
    "ord_in_thread": 0,
    "title": "BRIEF-Enanta Pharmaceuticals Reports Q2 Earnings Per Share $0.61",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 8 (Reuters) - Enanta Pharmaceuticals Inc:\n* ENANTA PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR ITS FISCAL SECOND QUARTER ENDED MARCH 31, 2018\n* Q2 EARNINGS PER SHARE $0.61 * Q2 EARNINGS PER SHARE VIEW $0.53 — THOMSON REUTERS I/B/E/S\n* ROYALTY REVENUE FOR QUARTER INCREASED TO $44.0 MILLION DUE TO INCREASE IN ABBVIE’S MAVYRET SALES\n* QTRLY TOTAL REVENUE WAS $44.0 MILLION, COMPARED TO $9.0 MILLION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-09T04:05:00.000+03:00",
    "crawled": "2018-05-09T12:39:30.008+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "enanta",
        "pharmaceutical",
        "inc",
        "enanta",
        "pharmaceutical",
        "report",
        "financial",
        "result",
        "fiscal",
        "second",
        "quarter",
        "ended",
        "march",
        "q2",
        "earnings",
        "per",
        "share",
        "q2",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "royalty",
        "revenue",
        "quarter",
        "increased",
        "million",
        "due",
        "increase",
        "abbvie",
        "mavyret",
        "sale",
        "qtrly",
        "total",
        "revenue",
        "million",
        "compared",
        "million",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}